skip to content
home ver. 2.3. site index contact us
Schering-Plough
About Us Products and Care R&D Partnerships News and Media Investor Relations Corporate Responsibility Careers
Message from the CEO
How We Work
History of Schering-Plough
Management Team
Schering-Plough Worldwide
Speeches & Presentations
The Schering-Plough Foundation
Diversity & Inclusion
Supplier Registration
Diversity Colleague Demographics

Management Team

ROBERT J. BERTOLINI
Executive Vice President and Chief Financial Officer
Schering-Plough Corporation
Kenilworth, New Jersey

Robert Bertolini is executive vice president and chief financial officer of Schering-Plough Corporation.

Bertolini joined Schering-Plough in his present position in November 2003. He is responsible for building a dynamic global finance team that comprises key financial areas, including taxes, accounting, internal audits, financial asset management, external financial relations, investments for employee benefit plans, and risk management and insurance. Additionally, he has responsibility for global information technology and business development.

In his previous role at PricewaterhouseCoopers, Bertolini managed the global pharmaceutical industry practice. He has extensive experience in audit, financial controls and corporate governance as well as in acting as a senior adviser to top management on financial and general business issues, including licensing and M&A transactions. Bertolini began his professional career at the former Coopers & Lybrand in 1983 and rose steadily through the company's professional ranks, serving blue-chip global clients in the pharmaceutical industry.

Bertolini graduated with a B.A. degree in economics from Rutgers University. He is a Certified Public Accountant.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

 

Spotlight On

Combination Brochure

Brochure on the Combination

Basic Facts and Figures
•  World Headquarters:
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530
•  Chairman and CEO:
Fred Hassan
Number of employees:
55,000
Net sales (2007):
$12.7 billion
Business operations in more than:
140 countries
Largest-selling products:
VYTORIN*, ZETIA*, REMICADE, NASONEX.
R&D investment (2007):
$2.9 billion
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health

*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
HomeAbout UsProducts & CareR&DPartnerships
News & MediaInvestor RelationsCorporate ResponsibilityCareers
Contact Us Site Index
© 2003 - 2008 Schering-Plough Corporation.
Please see our legal notice, privacy policy and forward-looking statement.
Schering-Plough Schering-Plough skip to content Schering-Plough